A New Era of Vaccines
For Sweden

Novavax, Inc. is a global biotechnology company committed to helping address serious infectious disease globally through the discovery, development, and delivery of innovative vaccines to patients around the world.

Our technology

Our vaccine technology leverages our proprietary recombinant protein-based nanoparticle technology and the immunogenicity-enhancing properties of our Matrix-M™ adjuvant.

Nanoparticles: By organizing recombinant proteins in a nanoparticle, it may help the immune system recognize that target protein from different angles1—the same way that the immune system would see the details of a real pathogen. In our vaccines, there’s no actual virus, just the protein; therefore, these vaccines can't cause disease.

Matrix-M adjuvant: Our Matrix-M adjuvant comes from saponins, naturally occurring compounds in the bark of the Quillaja saponaria (Soapbark) tree, commonly found in Chile. Saponins have a long history of being used for their medicinal properties.2 A vaccine containing another saponin-based adjuvant has previously been approved by the European Medicines Agency (EMA).3

Our areas of research

The world urgently needs new tools to help solve some of our greatest infectious disease challenges. Novavax is applying our unique technology to address current, emerging, and future public health threats. Novavax continually conducts clinical trials, investigations, and gathers real-world evidence in order to develop vaccines to address public health threats. Our scientists in our research and development (R&D) programs are committed to the efficient delivery of new vaccines while maintaining the safety of participants who take part in our trials.

Our areas of research

Our product

Nuvaxovid dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted)

For healthcare professionals, please visit  https://se.novavaxcovidvaccine.com/hcp

For more information, please contact your healthcare professional.

Contact us

For all general inquiries, please email us and we will be happy to respond within a few days.

  1. Krueger S, et al. Structural characterization and modeling of a respiratory syncytial virus fusion glycoprotein nanoparticle vaccine in solution. Mol Pharm. 2021;18(1):359–376.
  2. Marciani DJ. Elucidating the mechanisms of action of saponin-derived adjuvants. Trends Pharmacol Sci. 2018;39(6):573-585.
  3. Shingrix. Prescribing information. GSK; 2017.